Mariela Laura Paz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mariela Laura Paz has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Daniel H. Gonzalez Maglio
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología Buenos Aires Argentina
8 shared publications Juliana Leoni
Facultad de Farmacia y Bioquímica, CONICET-Universidad de Buenos Aires, Instituto de Estudios de la Inmunidad Humoral (IDEHU), CABA, Cuidad Autónoma de Buenos Aires, Argentina
6 shared publications- Pablo Evelson
Universidad de Buenos Aires. Instituto de Bioquímica y Medicina Molecular (IBIMOL UBA-CONICET), Facultad de Farmacia y Bioquímica
3 shared publications - Timoteo Marchini
Cardiology and Angiology (J.W., A.H., D.S., J.E., L.K., T.M., M.C.G., I.H., C.v.z.M., D. Westermann, P.S., D. Wolf, J.M.), Faculty of Medicine, University of Freiburg, Germany
3 shared publications - Adrián David Friedrich
Laboratorio de Fisiopatología de la Inmunidad Innata (IBYME-CONICET), Buenos Aires, Argentina
2 shared publications Federico S. Weill
University of Buenos Aires
2 shared publications
Latest Publications
- 25 March 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (8) , 4071-4072
AChR-blocking antibodies and complement system dynamics: evaluating their interplay and clinical implications in myasthenia gravis
- 25 March 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (8) , 4071-4072
AChR-blocking antibodies and complement system dynamics: evaluating their interplay and clinical implications in myasthenia gravis
- 16 December 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (4) , 1827-1832
AChR-blocking antibodies and complement system dynamics: evaluating their interplay and clinical implications in myasthenia gravis
Background Myasthenia gravis (MG) is an autoimmune disorder characterised by autoantibodies (abs) targeting proteins at the neuromuscular junction, primarily the acetylcholine receptor (AChR). While the role of AChR-binding abs is well-established, the pathogenicity and clinical relevance of AChR-blocking antibodies in MG, and their association with complement system, remain less understood. Aims This study aims to provide comprehensive insights into the prevalence and interplay of AChR-blocking antibodies and the complement system in an Argentinian MG cohort, investigating their relationships with disease activity. Methods We studied 75 MG patients with detectable AChR-binding abs, assessing the presence of AChR-blocking abs and complement components C3, C4, and C5a. We also examined clinical severity using the Activities of Daily Living and MG Composite scores. Correlation analyses were made to elucidate associations. Results AChR-blocking abs were detected in 49.3% of the patients. An inverse correlation was found between AChR-blocking abs titres and disease severity, with a higher titre associated with milder symptoms. Complement analysis revealed higher C4 levels in the AChR-blocking abs positive group, indicating reduced complement activation. Conclusion Our study provides valuable insights into the prevalence of AChR-blocking antibodies. Higher AChR-blocking abs titres were associated with less severe MG and reduced complement system activation, indicating a potential protective mechanism for those abs. These findings suggest that AChR-blocking abs could serve as a potential biomarker for a milder disease course and highlight the need for further research to understand their role in MG pathology, which will improve strategies for clinical management and diagnosis.
- 16 December 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (4) , 1827-1832
AChR-blocking antibodies and complement system dynamics: evaluating their interplay and clinical implications in myasthenia gravis
Background Myasthenia gravis (MG) is an autoimmune disorder characterised by autoantibodies (abs) targeting proteins at the neuromuscular junction, primarily the acetylcholine receptor (AChR). While the role of AChR-binding abs is well-established, the pathogenicity and clinical relevance of AChR-blocking antibodies in MG, and their association with complement system, remain less understood. Aims This study aims to provide comprehensive insights into the prevalence and interplay of AChR-blocking antibodies and the complement system in an Argentinian MG cohort, investigating their relationships with disease activity. Methods We studied 75 MG patients with detectable AChR-binding abs, assessing the presence of AChR-blocking abs and complement components C3, C4, and C5a. We also examined clinical severity using the Activities of Daily Living and MG Composite scores. Correlation analyses were made to elucidate associations. Results AChR-blocking abs were detected in 49.3% of the patients. An inverse correlation was found between AChR-blocking abs titres and disease severity, with a higher titre associated with milder symptoms. Complement analysis revealed higher C4 levels in the AChR-blocking abs positive group, indicating reduced complement activation. Conclusion Our study provides valuable insights into the prevalence of AChR-blocking antibodies. Higher AChR-blocking abs titres were associated with less severe MG and reduced complement system activation, indicating a potential protective mechanism for those abs. These findings suggest that AChR-blocking abs could serve as a potential biomarker for a milder disease course and highlight the need for further research to understand their role in MG pathology, which will improve strategies for clinical management and diagnosis.
- Open Access
- 8 September 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (39) , 27391-27402
Amidinoquinoxaline N -oxides: synthesis and activity against anaerobic bacteria
Amidinoquinoxaline N -oxides 1 show high antianaerobic activity, with CIM significantly lower than metronidazole in six cases, along with low cytotoxicity and promising ADME profiles. These nitrones represent a promising alternative to metronidazole.
- 8 September 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (39) , 27391-27402
Open AccessAmidinoquinoxaline N -oxides: synthesis and activity against anaerobic bacteria
Amidinoquinoxaline N -oxides 1 show high antianaerobic activity, with CIM significantly lower than metronidazole in six cases, along with low cytotoxicity and promising ADME profiles. These nitrones represent a promising alternative to metronidazole.
- 7 April 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (4) , 1447-1451
C5a complement levels in clinical remission AQP4-IgG-positive NMO patients
Background Neuromyelitis Optica Spectrum Disorders (NMOSD) is an antibody-mediated disorder of the Central Nervous System where a leading role of the complement system has been demonstrated. Objective To measure the levels of complement factors C3, C4 and C5a in serum and plasma of clinical remission patients with AQP4-IgG + NMOSD. Methods Twelve patients with NMOSD AQP4 + according to 2015 criteria from a General Hospital in Buenos Aires, Argentina, were included in the study, and 19 age- and sex-matched healthy volunteers as a control group (HC). AQP4 antibodies were measured in serum by CBA analysis. Fresh blood samples were centrifuged to obtain serum and plasma. C3, C4, and AQP4 antibodies were measured in the serum, whereas C5a was measured in the plasma, which was obtained using Futhan (BD FUT-175®, BD Biosciences, San Jose, CA, USA). Results The complement factors, C3, C4, and C5a were measured in all samples. The mean concentration of C3 was 130.7 mg/dl (SD 16.1 mg/dl), and the mean concentration of C4 was 21.6 mg/dl (SD 4.8 mg/dl); both values were within the normal reference range (C3: 84–193 mg/dl; C4: 20–40 mg/dl) and were not significantly different (p > 0.05) from the mean levels in healthy controls (C3: 116.9 mg/dl; C4: 21.9 mg/dl). When analyzing the mean plasma level of C5a, we found a statistically significant difference (p = 0.0444) between the mean concentration of C5a in NMOSD patients (43.1 ng/ml; SD 48.7 ng/ml) and the HC group (17.7 ng/ml; SD 16.7 ng/ ml). Conclusions In conclusion, the present study demonstrates that plasma C5a may be interesting to investigate as a potential biomarker of disease activity in NMOSD, in a larger and prospective cohort.
- 7 April 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (4) , 1447-1451
C5a complement levels in clinical remission AQP4-IgG-positive NMO patients
Background Neuromyelitis Optica Spectrum Disorders (NMOSD) is an antibody-mediated disorder of the Central Nervous System where a leading role of the complement system has been demonstrated. Objective To measure the levels of complement factors C3, C4 and C5a in serum and plasma of clinical remission patients with AQP4-IgG + NMOSD. Methods Twelve patients with NMOSD AQP4 + according to 2015 criteria from a General Hospital in Buenos Aires, Argentina, were included in the study, and 19 age- and sex-matched healthy volunteers as a control group (HC). AQP4 antibodies were measured in serum by CBA analysis. Fresh blood samples were centrifuged to obtain serum and plasma. C3, C4, and AQP4 antibodies were measured in the serum, whereas C5a was measured in the plasma, which was obtained using Futhan (BD FUT-175®, BD Biosciences, San Jose, CA, USA). Results The complement factors, C3, C4, and C5a were measured in all samples. The mean concentration of C3 was 130.7 mg/dl (SD 16.1 mg/dl), and the mean concentration of C4 was 21.6 mg/dl (SD 4.8 mg/dl); both values were within the normal reference range (C3: 84–193 mg/dl; C4: 20–40 mg/dl) and were not significantly different (p > 0.05) from the mean levels in healthy controls (C3: 116.9 mg/dl; C4: 21.9 mg/dl). When analyzing the mean plasma level of C5a, we found a statistically significant difference (p = 0.0444) between the mean concentration of C5a in NMOSD patients (43.1 ng/ml; SD 48.7 ng/ml) and the HC group (17.7 ng/ml; SD 16.7 ng/ ml). Conclusions In conclusion, the present study demonstrates that plasma C5a may be interesting to investigate as a potential biomarker of disease activity in NMOSD, in a larger and prospective cohort.
- Open Access
Lipoteichoic Acid from Lacticaseibacillus rhamnosus GG Modulates Dendritic Cells and T Cells in the Gut
Lipoteichoic acid (LTA) from Gram-positive bacteria exerts different immune effects depending on the bacterial source from which it is isolated. Lacticaseibacillus rhamnosus GG LTA (LGG-LTA) oral administration reduces UVB-induced immunosuppression and skin tumor development in mice. In the present work, we evaluate the immunomodulatory effect exerted by LGG-LTA in dendritic cells (DC) and T cells, both in vitro and in the gut-associated lymphoid tissue (GALT). During cell culture, LTA-stimulated BMDC increased CD86 and MHC-II expression and secreted low levels of pro and anti-inflammatory cytokines. Moreover, LTA-treated BMDC increased T cell priming capacity, promoting the secretion of IL-17A. On the other hand, in orally LTA-treated mice, a decrease in mature DC (lamina propria and Peyer’s patches) was observed. Concomitantly, an increase in IL-12p35 and IFN-γ transcription was presented (lamina propria and Peyer’s Patches). Finally, an increase in the number of CD103+ DC was observed in Peyer’s patches. Together, our data demonstrate that LGG-LTA activates DC and T cells. Moreover, we show that a Th1-biased immune response is triggered in vivo after oral LTA administration. These effects justify the oral LTA activity previously observed.
Open AccessLipoteichoic Acid from Lacticaseibacillus rhamnosus GG Modulates Dendritic Cells and T Cells in the Gut
Lipoteichoic acid (LTA) from Gram-positive bacteria exerts different immune effects depending on the bacterial source from which it is isolated. Lacticaseibacillus rhamnosus GG LTA (LGG-LTA) oral administration reduces UVB-induced immunosuppression and skin tumor development in mice. In the present work, we evaluate the immunomodulatory effect exerted by LGG-LTA in dendritic cells (DC) and T cells, both in vitro and in the gut-associated lymphoid tissue (GALT). During cell culture, LTA-stimulated BMDC increased CD86 and MHC-II expression and secreted low levels of pro and anti-inflammatory cytokines. Moreover, LTA-treated BMDC increased T cell priming capacity, promoting the secretion of IL-17A. On the other hand, in orally LTA-treated mice, a decrease in mature DC (lamina propria and Peyer’s patches) was observed. Concomitantly, an increase in IL-12p35 and IFN-γ transcription was presented (lamina propria and Peyer’s Patches). Finally, an increase in the number of CD103+ DC was observed in Peyer’s patches. Together, our data demonstrate that LGG-LTA activates DC and T cells. Moreover, we show that a Th1-biased immune response is triggered in vivo after oral LTA administration. These effects justify the oral LTA activity previously observed.
- 18 April 2021
- Published by Wiley in Photochemistry and Photobiology
- Vol. 97 (5) , 1145-1149
Low Vitamin D Serum Levels in a Cohort of Myasthenia Gravis Patients in Argentina
There are limited and controversial studies that address the role of vitamin D (vitD), a vitamin with immunomodulatory effects, in myasthenia gravis (MG), a neuromuscular autoimmune disease. We aimed to assess 25‐hydroxy vitamin D (25(OH)D) levels and to evaluate possible associations with the clinical severity and other biomarkers of the disease. Serum levels of 25(OH)D, anti‐acetylcholine receptor antibodies and complement factor C5a were measured in MG patients ( n = 66) and healthy volunteers (HV) ( n = 25). Participants were evaluated through questionnaires to determine vitD intake and sunlight exposure. Severity scores were registered for MG patients. We found an 89.4% of MG individuals with nonsufficient levels of vitD, in comparison with 68.0% in the group of HV (OR = 3.96; P = 0.024). In addition, there was an inverse correlation between 25(OH)D levels and one of the scores ( P = 0.037 r = −0.26, CI 95 = −0.49 to −0.0087). However, when we compared 25(OH)D median serum levels between MG patients and HV, no statistically significant differences have been found. This is the first report of vitD status in a cohort of Argentinean MG patients, where we found that patients are more likely to have nonsufficient levels of vitD compared to healthy people and that patients with more severe disease have lower levels of vitD.
- 18 April 2021
- Published by Wiley in Photochemistry and Photobiology
- Vol. 97 (5) , 1145-1149
Low Vitamin D Serum Levels in a Cohort of Myasthenia Gravis Patients in Argentina
There are limited and controversial studies that address the role of vitamin D (vitD), a vitamin with immunomodulatory effects, in myasthenia gravis (MG), a neuromuscular autoimmune disease. We aimed to assess 25‐hydroxy vitamin D (25(OH)D) levels and to evaluate possible associations with the clinical severity and other biomarkers of the disease. Serum levels of 25(OH)D, anti‐acetylcholine receptor antibodies and complement factor C5a were measured in MG patients ( n = 66) and healthy volunteers (HV) ( n = 25). Participants were evaluated through questionnaires to determine vitD intake and sunlight exposure. Severity scores were registered for MG patients. We found an 89.4% of MG individuals with nonsufficient levels of vitD, in comparison with 68.0% in the group of HV (OR = 3.96; P = 0.024). In addition, there was an inverse correlation between 25(OH)D levels and one of the scores ( P = 0.037 r = −0.26, CI 95 = −0.49 to −0.0087). However, when we compared 25(OH)D median serum levels between MG patients and HV, no statistically significant differences have been found. This is the first report of vitD status in a cohort of Argentinean MG patients, where we found that patients are more likely to have nonsufficient levels of vitD compared to healthy people and that patients with more severe disease have lower levels of vitD.
- 1 January 2021
- Published by Elsevier
- p. 285-308
Bioenergetic profiling in the skin
- Open Access
- 1 December 2020
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 205, 111186
NADPH oxidase and mitochondria are relevant sources of superoxide anion in the oxinflammatory response of macrophages exposed to airborne particulate matter
- 1 December 2020
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 205, 111186
Open AccessNADPH oxidase and mitochondria are relevant sources of superoxide anion in the oxinflammatory response of macrophages exposed to airborne particulate matter
- Open Access
- 31 August 2018
- Published by Asociación Bioquímica Argentina in Revista Bioquímica y Patología Clínica
- Vol. 82 (3) , 12-17
Nueva prueba diagnóstica para autoanticuerpos en Miastenia Gravis basado en un sistema de micropartículas fluorescentes libre de células
Introducción: Se ha desarrollado una novedosa prueba diagnóstica para la detección de autoanticuerpos en pacientes con miastenia gravis. Este nuevo método, libre de células, es relativamente simple y consume menos tiempo y materiales que el radioinmunoensayo estándar, método de referencia utilizado actualmente en la clínica. Materiales y métodos: La prueba consiste en el uso de micropartículas de poliestireno recubiertas con el receptor de acetilcolina (se probaron dos fuentes de receptor de diferente origen), marcación específica del receptor con ligandos fluorescentes de alta afinidad (α-bungarotoxina-AlexaFluor o anticuerpos anti-receptor policlonales provenientes de los sueros de pacientes diagnosticados con la enfermedad, seguidos de anticuerpos secundarios conjugados con fluorocromos), y detección por citometría de flujo. Resultados: Los valores de intensidad de fluorescencia media para los sueros positivos por la técnica de referencia versus un pool de sueros humanos normales: mostraron una diferencia estadísticamente significativa para los dos tipos de micropartículas sensibilizadas utilizadas. Conclusión: Las dos estrategias diferentes evaluadas fueron exitosas para la detección de autoanticuerpos en el suero de pacientes con miastenia gravis. Adicionalmente esta prueba tiene el potencial para distinguir entre las distintas formas de los anticuerpos anti-receptor de acetilcolina, y los resultados podrían correlacionarse con la severidad de la miastenia gravis, pudiendo resultar un elemento predictivo de gran utilidad en el seguimiento de la evolución clínica de la enfermedad.
- 31 August 2018
- Published by Asociación Bioquímica Argentina in Revista Bioquímica y Patología Clínica
- Vol. 82 (3) , 12-17
Open AccessNueva prueba diagnóstica para autoanticuerpos en Miastenia Gravis basado en un sistema de micropartículas fluorescentes libre de células
Introducción: Se ha desarrollado una novedosa prueba diagnóstica para la detección de autoanticuerpos en pacientes con miastenia gravis. Este nuevo método, libre de células, es relativamente simple y consume menos tiempo y materiales que el radioinmunoensayo estándar, método de referencia utilizado actualmente en la clínica. Materiales y métodos: La prueba consiste en el uso de micropartículas de poliestireno recubiertas con el receptor de acetilcolina (se probaron dos fuentes de receptor de diferente origen), marcación específica del receptor con ligandos fluorescentes de alta afinidad (α-bungarotoxina-AlexaFluor o anticuerpos anti-receptor policlonales provenientes de los sueros de pacientes diagnosticados con la enfermedad, seguidos de anticuerpos secundarios conjugados con fluorocromos), y detección por citometría de flujo. Resultados: Los valores de intensidad de fluorescencia media para los sueros positivos por la técnica de referencia versus un pool de sueros humanos normales: mostraron una diferencia estadísticamente significativa para los dos tipos de micropartículas sensibilizadas utilizadas. Conclusión: Las dos estrategias diferentes evaluadas fueron exitosas para la detección de autoanticuerpos en el suero de pacientes con miastenia gravis. Adicionalmente esta prueba tiene el potencial para distinguir entre las distintas formas de los anticuerpos anti-receptor de acetilcolina, y los resultados podrían correlacionarse con la severidad de la miastenia gravis, pudiendo resultar un elemento predictivo de gran utilidad en el seguimiento de la evolución clínica de la enfermedad.